These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 21220306)

  • 1. Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.
    Franco AT; Malaguarnera R; Refetoff S; Liao XH; Lundsmith E; Kimura S; Pritchard C; Marais R; Davies TF; Weinstein LS; Chen M; Rosen N; Ghossein R; Knauf JA; Fagin JA
    Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1615-20. PubMed ID: 21220306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyrotropin signaling confers more aggressive features with higher genomic instability on BRAF(V600E)-induced thyroid tumors in a mouse model.
    Orim F; Bychkov A; Shimamura M; Nakashima M; Ito M; Matsuse M; Kurashige T; Suzuki K; Saenko V; Nagayama Y; Yamashita S; Mitsutake N
    Thyroid; 2014 Mar; 24(3):502-10. PubMed ID: 23924149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.
    Zou M; Baitei EY; Al-Rijjal RA; Parhar RS; Al-Mohanna FA; Kimura S; Pritchard C; Binessa HA; Alzahrani AS; Al-Khalaf HH; Hawwari A; Akhtar M; Assiri AM; Meyer BF; Shi Y
    Oncogene; 2016 Apr; 35(15):1909-18. PubMed ID: 26477313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postnatal expression of BRAFV600E does not induce thyroid cancer in mouse models of thyroid papillary carcinoma.
    Shimamura M; Nakahara M; Orim F; Kurashige T; Mitsutake N; Nakashima M; Kondo S; Yamada M; Taguchi R; Kimura S; Nagayama Y
    Endocrinology; 2013 Nov; 154(11):4423-30. PubMed ID: 23970782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
    Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
    Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of iodine metabolism genes in human thyroid tissues: evidence for age and BRAFV600E mutation dependency.
    Espadinha C; Santos JR; Sobrinho LG; Bugalho MJ
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):629-35. PubMed ID: 18710471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-regulation between oncogenic BRAF(V600E) kinase and the MST1 pathway in papillary thyroid carcinoma.
    Lee SJ; Lee MH; Kim DW; Lee S; Huang S; Ryu MJ; Kim YK; Kim SJ; Kim SJ; Hwang JH; Oh S; Cho H; Kim JM; Lim DS; Jo YS; Shong M
    PLoS One; 2011 Jan; 6(1):e16180. PubMed ID: 21249150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS(G12D)-mediated oncogenic transformation of thyroid follicular cells requires long-term TSH stimulation and is regulated by SPRY1.
    Zou M; Baitei EY; Al-Rijjal RA; Parhar RS; Al-Mohanna FA; Kimura S; Pritchard C; BinEssa H; Alanazi AA; Alzahrani AS; Akhtar M; Assiri AM; Meyer BF; Shi Y
    Lab Invest; 2015 Nov; 95(11):1269-77. PubMed ID: 26146959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
    Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse.
    Charles RP; Iezza G; Amendola E; Dankort D; McMahon M
    Cancer Res; 2011 Jun; 71(11):3863-71. PubMed ID: 21512141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
    McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
    Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene.
    Lin JD; Fu SS; Chen JY; Lee CH; Chau WK; Cheng CW; Wang YH; Lin YF; Fang WF; Tang KT
    Thyroid; 2016 May; 26(5):691-704. PubMed ID: 26914762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-12 immunotherapy of Braf(V600E)-induced papillary thyroid cancer in a mouse model.
    Parhar RS; Zou M; Al-Mohanna FA; Baitei EY; Assiri AM; Meyer BF; Shi Y
    Lab Invest; 2016 Jan; 96(1):89-97. PubMed ID: 26501867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing.
    Kleiman DA; Buitrago D; Crowley MJ; Beninato T; Veach AJ; Zanzonico PB; Jin M; Fahey TJ; Zarnegar R
    J Surg Res; 2013 Jun; 182(1):85-93. PubMed ID: 22998776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status.
    Khan MS; Pandith AA; Masoodi SR; Wani KA; Ul Hussain M; Mudassar S
    Endocrine; 2014 Nov; 47(2):449-55. PubMed ID: 24927793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling.
    Knauf JA; Sartor MA; Medvedovic M; Lundsmith E; Ryder M; Salzano M; Nikiforov YE; Giordano TJ; Ghossein RA; Fagin JA
    Oncogene; 2011 Jul; 30(28):3153-62. PubMed ID: 21383698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
    Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
    Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation.
    Franzoni A; Dima M; D'Agostino M; Puppin C; Fabbro D; Loreto CD; Pandolfi M; Puxeddu E; Moretti S; Celano M; Bruno R; Filetti S; Russo D; Damante G
    Thyroid; 2009 Mar; 19(3):247-55. PubMed ID: 19207009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF
    Hernandez BY; Rahman M; Loo LWM; Chan OTM; Horio D; Morita S; Bryant-Greenwood G
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):183-194. PubMed ID: 32995956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.